| Migraine Disorders
Botox vs Reyvow
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Botox vs Reyvow with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsReyvow has a higher rate of injection site reactions vs Botox based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Reyvow but not Botox, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Botox
Reyvow
At A Glance
IM injection
Every 12 weeks
Botulinum toxin type A
Oral
As needed
5-HT1F receptor agonist
Indications
- Overactive Bladder
- Migraine Disorders
- Benign essential blepharospasm
- Strabismus, Comitant
- Migraine Disorders
Dosing
Overactive Bladder 100 Units injected as 0.5 mL (5 Units) across 20 sites into the detrusor via cystoscope; repeat no sooner than 12 weeks.
Detrusor Overactivity associated with a Neurologic Condition 200 Units injected as 1 mL (~6.7 Units) across 30 sites into the detrusor via cystoscope; repeat no sooner than 12 weeks.
Pediatric Detrusor Overactivity associated with a Neurologic Condition 200 Units (>=34 kg) or 6 Units/kg (<34 kg) via intradetrusor injection across 20 sites; repeat no sooner than 12 weeks.
Migraine Disorders 155 Units IM as 0.1 mL (5 Units) per site divided across 7 head/neck muscle areas; re-treat every 12 weeks.
Adult Upper Limb Spasticity 75-400 Units IM divided among affected muscles; re-treat no sooner than 12 weeks.
Adult Lower Limb Spasticity 300-400 Units IM divided across 5 muscles (gastrocnemius, soleus, tibialis posterior, flexor hallucis longus, flexor digitorum longus); re-treat no sooner than 12 weeks.
Pediatric Upper Limb Spasticity 3-6 Units/kg IM (maximum 200 Units) divided among affected muscles; re-treat no sooner than 12 weeks.
Pediatric Lower Limb Spasticity 4-8 Units/kg IM (maximum 300 Units) divided among affected muscles; re-treat no sooner than 12 weeks.
Cervical Dystonia Dose individualized based on head/neck position, pain, and muscle hypertrophy; mean dose approximately 236 Units IM divided among affected muscles.
Primary Axillary Hyperhidrosis 50 Units per axilla injected intradermally across 10-15 sites approximately 1-2 cm apart.
Benign essential blepharospasm 1.25-2.5 Units injected into 3 sites per affected eye; re-treat approximately every 3 months.
Strabismus, Comitant 1.25-5 Units per muscle via electromyographic-guided injection, dosed based on deviation size in prism diopters; re-examine 7-14 days after each injection.
Migraine Disorders 50 mg, 100 mg, or 200 mg orally as needed; no more than one dose in 24 hours; wait at least 8 hours between dosing and driving or operating machinery; swallow tablets whole.
Contraindications
- Hypersensitivity to any botulinum toxin product or to any component of the formulation
- Infection at the proposed injection site(s)
- Urinary tract infection at time of intradetrusor injection
- Urinary retention or post-void residual urine volume >200 mL in patients not routinely performing clean intermittent self-catheterization (for intradetrusor injection)
—
Adverse Reactions
Most common (>=2%) Urinary tract infection, dysuria, urinary retention, neck pain, headache, muscular weakness, eyelid ptosis, injection site pain, dysphagia, upper respiratory infection
Serious Spread of toxin effects, dysphagia and breathing difficulties, hypersensitivity reactions, autonomic dysreflexia, corneal exposure and ulceration, retrobulbar hemorrhage
Postmarketing Abdominal pain, alopecia, brachial plexopathy, peripheral neuropathy, arrhythmia, myocardial infarction, death associated with dysphagia and pneumonia, new onset or recurrent seizures
Most common (>=2%) dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, muscle weakness
Serious hypersensitivity reactions including angioedema, rash, and photosensitivity reaction
Pharmacology
Botulinum toxin type A that blocks neuromuscular transmission by inhibiting acetylcholine release at motor and autonomic nerve terminals through cleavage of SNAP-25, producing localized, reversible chemical denervation of muscle, sweat glands, or the detrusor depending on injection site.
5-HT1F receptor agonist; lasmiditan binds with high affinity to the 5-HT1F receptor and presumably exerts its therapeutic effects in migraine through agonist activity at this receptor, though the precise mechanism is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Botox
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (0/12)
Reyvow
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Botox
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Reyvow
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (5/8) · Qty limit (4/8)
Humana
Botox
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Reyvow
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Reyvow.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.